By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Isarna Therapeutics 

Josef-Engert-Strasse 9

Regensburg    D-93053  Germany
Phone: 49-941-9201-30 Fax: 49-941-9201-329


Company News
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015 11:05:47 AM
Isarna Therapeutics Raises Euro 5.5 Million, Announces Elizabeth Czerepak Joining As CFO/CBO To Lead U.S. Site 4/24/2014 9:55:21 AM
Isarna Therapeutics Enters Into A Strategic Manufacturing Agreement With Sanofi (France) (SAN.PA) 1/9/2014 12:50:53 PM
Isarna Therapeutics And Santaris Pharma A/S Announce License Agreement For The Development Of Next Generation Oligonucleotides To Treat TGF-Beta-Mediated Diseases 1/8/2014 9:52:47 AM
Antisense Pharma Changes Name to Isarna Therapeutics 9/30/2013 9:42:35 AM
ANTISENSE PHARMA GmbH Announces Revised Development Path for Trabedersen 2/26/2013 11:14:38 AM
ANTISENSE PHARMA GmbH Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma 7/24/2012 9:52:34 AM
ANTISENSE PHARMA GmbH Presents Trabedersen Phase I/II Complete Data at American Society of Clinical Oncology 6/4/2012 10:42:35 AM
Dr. Philippe Calais Appointed Chief Executive Officer of ANTISENSE PHARMA GmbH 5/10/2012 6:25:45 AM
ANTISENSE PHARMA GmbH Special Issue: Transforming Growth Factor Beta (TGF-ß) as a Target in Oncology 1/11/2012 10:02:31 AM